EPO Patent Bulletin - Antibodies Binding to Citrullinated Histone
Summary
The European Patent Office has published a patent bulletin regarding antibodies binding to citrullinated histone 2A and/or 4, filed by Citryll B.V. The patent, EP4659807A3, relates to antibodies or binding fragments thereof directed against citrulline-containing epitopes, potentially for therapeutic use in Neutrophil Extracellular Trap (NET)-associated pathologies.
What changed
The European Patent Office (EPO) has issued a patent bulletin (EP4659807A3) for Citryll B.V., detailing "Antibodies binding to citrullinated histone 2A and/or 4." The patent abstract describes antibodies or binding fragments thereof that target citrulline-containing epitopes, with potential applications in the therapy or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.
This publication is a patent grant and does not impose direct compliance obligations on regulated entities. However, companies involved in the development or research of antibodies for autoimmune or inflammatory conditions, particularly those related to NETs, should be aware of this granted patent. It may impact intellectual property strategies and competitive landscapes within the pharmaceutical and biotechnology sectors.
Source document (simplified)
ANTIBODIES BINDING TO CITRULLINATED HISTONE 2A AND/OR 4
Search Report EP4659807A3 Kind: A3 Mar 18, 2026
Applicants
Citryll B.V.
Inventors
RAATS, Jozef Maria Hendrik, CHIRIVI, Renato Gerardus Silvano, VAN ROSMALEN, Johannes Wilhelmus Gerardus
Abstract
The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.
IPC Classifications
C07K 16/18 20060101AFI20260211BHEP A61P 29/00 20060101ALI20260211BHEP A61P 19/02 20060101ALI20260211BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.